Objective To observe the therapeutic effect of general combinable external fixator for the treatment of femoral intertrochanteric fracture(FIF).Methods One hundred and seventeen FIF patients were randomized into two groups: the treatment group(N =56) received treatment with general combinable external fixator,and the control group(N =61) received bone traction.A follow-up of 6~13 months was carried out.The therapeutic effect and the incidence of complications were compared in both groups.Results The total effective rate was 96.43% in the treatment group and 50.82% in the control group,and the incidence of complications was 7.1%(4/56) in the treatment group and 45.9%(28/61)in the control group,the difference being significant(P

Objective Optimizing the preparation technology of Red buttock ointment,by exploring the best extraction conditions of the alkannin,radix arnebiae seu lithospermi polysaccharides and so on.Methods Selecting radix arnebiae seu lithospermi 1kg and using orthogonal experiment to explore the best extraction conditions.Naphtho-quinone pigment chemicals were extracted by reflux extraction method;ethanol and paraffin wax were chosen as the composite solvent.Radix arnebiae seu lithospermi polysaccharide was extracted by water decocting,which to observe the rationality of process.Results The best extraction condition is A3 B2 C1 D1 , including section A:ethanol was 20 times the quality of medicinal materials (select radix arnebiae seu lithospermi 1kg and ethanol 20kg),section B:the amount of paraffin was 5% of ethanol(select radix arnebiae seu lithospermi 1kg and paraffin 1 kg),section C:Boiling water was 20 times the quality of medicinal materials,section D:the boiling time was 2h.Conclusion The more practical production process conditions:Ethanol was 10 times the quality of medicinal materials,and the amount of paraffin was 5%of ethanol.Boiling water was 10 times the quality of medicinal materials,and the boiling time was 1 h.This method is economic, simple, reasonable, stable, reproducible and easy to operation.Red buttock ointment obtained by this method possesses of excellent quality,good performance and superior effect.

Objective:To assess the clinical effectiveness and safety of Omalizumab for treating pediatric allergic asthma in real world in China.Methods:The clinical data of children aged 6 to 11 years with allergic asthma who received Omalizumab treatment in 17 hospitals in China between July 6, 2018 and September 30, 2020 were retrospectively analyzed.Such information as the demographic characteristics, allergic history, family history, total immunoglobulin E (IgE) levels, specific IgE levels, skin prick test, exhaled nitric oxide (FeNO) levels, eosinophil (EOS) counts, and comorbidities at baseline were collected.Descriptive analysis of the Omalizumab treatment mode was made, and the difference in the first dose, injection frequency and course of treatment between the Omalizumab treatment mode and the mode recommended in the instruction was investigated.Global Evaluation of Treatment Effectiveness (GETE) analysis was made after Omalizumab treatment.The moderate-to-severe asthma exacerbation rate, inhaled corticosteroid (ICS) dose, lung functions were compared before and after Omalizumab treatment.Changes in the Childhood Asthma Control Test (C-ACT) and Pediatric Asthma Quality of Life Questionnaire (PAQLQ) results from baseline to 4, 8, 12, 16, 24, and 52 weeks after Omalizumab treatment were studied.The commodity improvement was assessed.The adverse event (AE) and serious adverse event (SAE) were analyzed for the evaluation of Omalizumab treatment safety.The difference in the annual rate of moderate-to-severe asthma exacerbation and ICS reduction was investigated by using t test.The significance level was set to 0.05.Other parameters were all subject to descriptive analysis.A total of 200 allergic asthma patients were enrolled, including 75.5% ( n=151) males and 24.5% ( n=49) females.The patients aged (8.20±1.81) years. Results:The median total IgE level of the 200 patients was 513.5 (24.4-11 600.0) IU/mL.Their median treatment time with Omalizumab was 112 (1-666) days.Their first dose of Omalizumab was 300 (150-600) mg.Of the 200 cases, 114 cases (57.0%) followed the first Omalizumab dosage recommended in the instruction.After 4-6 months of Omalizumab treatment, 88.5% of the patients enrolled ( n=117) responded to Omalizumab.After 4 weeks of treatment with Omalizumab, asthma was well-controlled, with an increased C-ACT score [from (22.70±3.70) points to (18.90±3.74) points at baseline]. Four-six months after Omalizumab administration, the annual rate of moderate-to-severe asthma exacerbation had a reduction of (2.00±5.68) per patient year( t=4.702 5, P<0.001), the median ICS daily dose was lowered [0 (0-240) μg vs. 160 (50-4 000) μg at baseline] ( P<0.001), the PAQLQ score was improved [(154.90±8.57) points vs. (122.80±27.15) points at baseline], and the forced expiratory volume in one second % predicted (FEV 1%pred) was increased [(92.80±10.50)% vs. (89.70±18.17)% at baseline]. In patients with available evaluations for comorbidities, including allergic rhinitis, atopic dermatitis or eczema, urticaria, allergic conjunctivitis and sinusitis, 92.8%-100.0% showed improved symptoms.A total of 124 AE were reported in 58 (29.0%) of the 200 patients, and the annual incidence was 0(0-15.1) per patient year.In 53 patients who suffered AE, 44 patients (83.0%) and 9 patients (17.0%) reported mild and moderate AE, respectively.No severe AE were observed in patients.The annual incidence of SAE was 0(0-1.9) per patient year.Most common drug-related AE were abdominal pain (2 patients, 1.0%) and fever (2 patients, 1.0%). No patient withdrew Omalizumab due to AE. Conclusions:Omalizumab shows good effectiveness and safety for the treatment of asthma in children.It can reduce the moderate-to-severe asthma exacerbation rate, reduce the ICS dose, improve asthma control levels, and improve lung functions and quality of life of patients.